// App-Quantinova.ai

5042 : Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.

Researchers

Presenter

  • Jing Li

Principal Investigators

  • Joshua Beaver

  • Rhonda Lynn Bitting

  • Simon Gregory

  • Andrew J. Armstrong

Medical Centers

  • Duke University Center for Human Genetics, Durham, NC

  • Duke University Medical Center, Chapel Hill, NCLabcorp, Raleigh, NCDuke Cancer Institute, Duke University, Durham, NC

  • Wake Forest University, Hillsborough, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Cluster of differentiation 45

  • Epithelial Cell Adhesion Molecule

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved